blue cross blue shield not covering glp 1 Alternatives to GLP-1 medication? Why we are changing coverage

The active ingredients semaglutide and tirzepatide have been studied extensively in their branded forms but the compounded versions dispensed through partner pharmacies have not undergone FDA premarket review as finished products

Growing up in Montreal, Canada, Drucker did his undergraduate studies at the University of Ottawa and then completed his internal medicine and endocrinology residencies at the University of Toronto, followed by postgraduate endocrinology training at Johns Hopkins Hospital

For patients preferring oral options, the Wegovy pill offers daily convenience without injections

Employer Benefits: Data on employer-provided coverage for GLP-1 agonists came from the KFF 2025 Employer Health Benefits Survey

This can get more people to their goals with fewer side effects

however, the potential for weight loss with the GLP-1 incretin mimetics can be a motivator for some patients